Cochrane COVID-19 Study Register
Study record
NCT05133609First Published: 2021 Nov 24Updated Date: 2021 Nov 24

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Prevention
  1. Study Design
  2. Other
  1. Intervention Assignment
  2. Non-randomised
Reference record

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

Federal University of Espirito Santo
First Published (first received 2021 November 24)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT05133609)
Trial registry record
No Results
A longitudinal open-label study will include health professionals and patients with immune-mediated inflammatory diseases (IMID) who will receive the ChAdOx1 nCoV-19 vaccine (AZD1222), in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-thrid dose), in the vaccination campaign against SARS-CoV-2 to assess the safety, efficacy and duration of the short- and long-term humoral and cellular immune response after vaccination for COVID-19 and compare the vaccine response between individuals who have or have not had previous SARS-Cov 2 infection